Jeff Galvin, a visionary biotech leader and entrepreneur, founded American Gene Technologies (AGT), where he serves as CEO, with a mission to pioneer revolutionary gene and cell therapies. AGT, a leading company in the field, focuses on developing potential cures for infectious diseases, cancers, and rare genetic disorders. Galvin’s commitment to innovation led to the establishment of Addimmune, an AGT subsidiary dedicated to finding a functional cure for HIV. With a BA in Economics from Harvard University and a background as a software engineer in Silicon Valley, Galvin’s entrepreneurial journey spans successful tech startups and ventures into medical technology. His multidisciplinary expertise in economics, software, and entrepreneurship drives AGT’s success, positioning the company as a leader in gene and cell therapy innovation.